Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of
intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present
with symptoms of acute ischemic stroke within 3 to 4.5 hours from onset.